Lamei Pharmaceuticals: Net loss of 135 million yuan in 2025

2026-04-07 10:58:51

LEMEI Pharmaceuticals announcement: In 2025, operating revenue was 7.76 billion yuan, down 2.50% year over year. The net loss attributable to shareholders of the listed company was 1.35 billion yuan; net loss in the same period last year was 87.8044 million yuan. The company plans not to distribute cash dividends, not to issue bonus shares, and not to convert capital reserves into share capital.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.